Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.53 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19005101 | 1.00 | TBK1 (0.53) | TBK1SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL18985504 | 0.85 | GABRP (0.45) | TBK1 | |
| SCHEMBL24492752 | 0.85 | GPR119 (0.53) | TBK1SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL19005022 | 0.84 | TBK1 (0.53) | TBK1GPR119 | |
| SCHEMBL18291487 | 0.84 | GPR119 (0.48) | TBK1SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL18291466 | 0.84 | GPR119 (0.48) | TBK1SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL30777918 | 0.82 | TBK1 (0.62) | TBK1 | |
| SCHEMBL20684921 | 0.82 | ALDH1A1 (0.47) | TBK1SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL18985904 | 0.82 | TBK1 (0.62) | TBK1 | |
| SCHEMBL18083774 | 0.82 | ALDH1A1 (0.47) | TBK1SMARCA2SMARCA4PBRM1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | TBK1 1468/4885SMARCA2 239/4885SMARCA4 164/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | TBK1 1468/4885SMARCA2 239/4885SMARCA4 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.